Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Diphenhydramine

Diphenhydramine

Diphenhydramine is a commonly used antihistamine medication that helps alleviate symptoms of allergies, such as sneezing, itching, and hives.
It works by blocking the action of histamine, a chemical released by the body during an allergic reaction.
Diphenhydramine is available in various forms, including oral tablets, capsules, and liquids, and is often used to treat conditions like hay fever, insect bites, and certain types of skin rashes.
Researchers use this medication in studies to understand its pharmacological properties and potential therapeutic applications.
PubCompare.ai can assist scientists in optimizing their Diphenhydramine research by helping them identify the best protocols and approaches from the literature, preprints, and patents, thus enhancing the reproducibility and accuracy of their findings.
Leveraging the platform's intelligent comparisons can lead to the most reliable and effective methodologies, ultimately improviing the quality of Diphenhydramine research.

Most cited protocols related to «Diphenhydramine»

1
Immunotoxin administration in swine
Cited 6 times
Four miniature swine, aged two months, were brought to our AAALAC accredited animal facility and were allowed to acclimate to their new surroundings for one week. Three days prior to the start of treatment they were bled for baseline blood values: complete blood counts, serum chemistry values and for flow cytometry analysis of CD3+ T cell populations. They were then injected through a 23g butterfly catheter, through a peripheral vessel, with an intravenous (IV) bolus of undiluted A-dmDT390biscFv (2-6-15) at a dose of 50 μg/kg, twice daily for 4 days. Prior to each day’s injections, morning blood samples were taken to monitor the aforementioned blood values. Each day’s values were then compared to the pre-treatment values. The animals were also injected with 4mg/kg diphenhydramine IV bolus immediately prior to immunotoxin infusion to prevent any unexpected anaphylactic reactions, of which none were observed. To ensure the full volume of immunotoxin was administered to the animals, each dose was flushed with 10 mL of phosphate buffered saline (pH of between 6.5 and 7.5). The animals were closely monitored for signs of change in clinical condition such as lethargy and significant weight loss and no signs of toxicity were seen in any animal. The animals were bled again on days 7 and 14 following the start of injections to monitor their T cell recovery and any possible toxicity.
The percentage of CD3+ T cells in the peripheral blood was determined by flow cytometry of heparinized whole blood samples after staining with FITC conjugated swine specific CD3 antibody (898H2-6-15, mouse IgGaK)13 using BD FACS lysing solution whole blood staining procedure according to the manufacturer (BD Biosciences, San Jose, Ca). The absolute T-cell count each day was calculated by multiplying the percentage of CD3+ cells in the peripheral blood by the white blood cell count. All experiments were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee.
Wang Z., Duran-Struuck R., Crepeau R., Matar A., Hanekamp I., Srinivasan S., Neville DM J.r., Sachs D.H, & Huang C.A. (2011). Development of a diphtheria toxin based anti-porcine CD3 recombinant immunotoxin. Bioconjugate chemistry, 22(10), 2014-2020.
Publication 2011
Anaphylactic Shock Animals BLOOD Blood Circulation Blood Vessel Butterflies Catheters Complete Blood Count Diphenhydramine Flow Cytometry Fluorescein-5-isothiocyanate Immunoglobulins Immunotoxins Institutional Animal Care and Use Committees Lethargy Leukocytes Mus Phosphates Pigs Population Group Saline Solution Serum Swine, Miniature T-Lymphocyte Vision
2
Phase 1/2 Teclistamab for Relapsed/Refractory Myeloma
Cited 5 times
Details regarding the phase 1 study design and methods have been reported previously.9 (link) In brief, eligible patients were 18 years of age or older and had a documented diagnosis of relapsed or refractory myeloma according to the criteria of the International Myeloma Working Group.10 (link) Patients must have previously received at least three lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody) and have had progressive, measurable disease at screening. Previous treatment with a BCMA-targeted therapy was not allowed. Eligible patients had a score of 0 or 1 on the Eastern Cooperative Oncology Group performance-status scale (which ranges from 0 to 5, with higher scores indicating greater disability). Full eligibility criteria are provided in the protocol, which is available with the full text of this article at NEJM.org.
Patients received once-weekly subcutaneous teclistamab at a dose of 1.5 mg per kilogram, which had been preceded by step-up doses of 0.06 and 0.3 mg per kilogram.9 (link) The step-up doses were separated by 2 to 4 days and were completed 2 to 4 days before the administration of the first full teclistamab dose. Hospitalization and pre-medication with dexamethasone (16 mg), acetaminophen, and diphenhydramine were required for each step-up dose and for the first full dose of teclistamab. The cycle duration was 21 days in phase 1 and 28 days in phase 2. Patients continued to receive teclistamab until the occurrence of disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study (defined as 2 years after the administration of the first dose of teclistamab in the last enrolled patient).
Oliveira D.C., Crisóstomo I., Santos-Sanches I., Major P., Alves C.R., Aires-de-Sousa M., Thege M.K, & de Lencastre H. (2001). Comparison of DNA Sequencing of the Protein A Gene Polymorphic Region with Other Molecular Typing Techniques for Typing Two Epidemiologically Diverse Collections of Methicillin-Resistant Staphylococcus aureus. Journal of Clinical Microbiology, 39(2), 574-580.
Publication 2022
Acetaminophen Aftercare Antibodies, Anti-Idiotypic Biological Response Modifiers bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine Dexamethasone Diagnosis Diphenhydramine Disabled Persons Disease Progression Eligibility Determination Hospitalization Multiple Myeloma Neoplasms Patients Pharmaceutical Preparations Proteasome Inhibitor Therapeutics
3
Molecular Docking of Bitter Agonists
Cited 5 times
Diphenhydramin, diphenidol, chlorpheniramin, chloroquin, chloramphenicol, and coumarin were analyzed as ggTas2r1 agonists. The 3D molecular structures of these compounds were downloaded from the publicly accessible electronic database, chicken BitterDB40 (link) (http://bitterdb/dbbitter.php?mode_organism=Chicken), and prepared (through the generation of stereoisomers and protonation states at pH 7 ± 0.5) with LigPrep (version 3.6, Schrödinger, LLC, New York, NY, 2015). Pose 7 model 1 resulted in agreement with mutagenesis studies and was used to predict the binding modes of other ggTas2r1 agonists.
Using docking settings described above, the grid of ggTas2r1 pose 7 model 1 structure was prepared and the ligands were docked into it. Generated docking poses were submitted to 10 parallel 24 hours of PELE simulations. 1299 poses were generated for diphenhydramine/ggTas2r1, 1939 for chlorpheniramine/ggTas2r1, 581 for diphenidol/ggTas2r1, 884 for chloroquine/ggTas2r1, 1733 for chloramphenicol/ggTas2r1, and 3324 for coumarin/ggTas2r1. Ligand-receptor complex structures were clustered (using the procedure described for quinine). Representative structures for each ligand were analyzed and binding modes were selected according to the mutagenesis data.
Di Pizio A., Kruetzfeldt L.M., Cheled-Shoval S., Meyerhof W., Behrens M, & Niv M.Y. (2017). Ligand binding modes from low resolution GPCR models and mutagenesis: chicken bitter taste receptor as a test-case. Scientific Reports, 7, 8223.
Full text: Click here
Publication 2017
agonists Chickens Chloramphenicol Chloroquine Chlorpheniramine coumarin Diphenhydramine diphenidol Ligands Mutagenesis Quinine Stereoisomers
4
Improving Sleep Quality in MICU Patients
Cited 4 times
This quality improvement (QI) project was undertaken in the Johns Hopkins MICU, which has a 1:2 registered nurse-to-patient ratio and 16 private rooms. This MICU-wide, pre-post evaluation was developed by a multi-disciplinary team with expertise in critical care, sleep, nursing, psychiatry, neuro-psychology, and pharmacology. The multi-faceted QI intervention targeted modifiable factors affecting sleep quality (1 (link),2 (link),4 ,14 ), and was implemented in three additive stages (described below), using a previously employed QI framework (15 (link)-17 ).
Baseline (January-February 2010): usual MICU care.
Stage 1 (starting March 2010): To decrease sleep disruptions, nighttime environmental interventions were implemented, including minimizing overhead pages, turning off patient televisions, dimming hallway lights, and grouping care activities (14 ,18 (link)). Daytime interventions to promote normal circadian rhythms and nighttime sleep included raising window blinds, preventing excessive napping, encouraging mobilization, and minimizing pre-bedtime caffeine.
Stage 2 (starting April 2010): In addition to Stage 1 interventions, previously studied non-pharmacological sleep aids were offered to non-delirious (as measured by a negative Confusion Assessment Method for the ICU [CAM-ICU] (19 (link)) assessment) patients, including earplugs (20 (link),21 (link)), eye masks (21 (link)), and soothing music (22 (link)).
Stage 3 (May-July 2010): A pharmacologic guideline was implemented for patients unable to sleep despite the Stage 1 and 2 interventions. This guideline discouraged use of commonly prescribed sedating medications known to alter sleep and precipitate delirium (i.e. benzodiazepines, opiates, diphenhydramine, trazodone) (12 (link),23 (link),24 (link)), and recommended readily available alternatives: 1)zolpidem for patients without delirium, and 2)haloperidol or an atypical antipsychotic for patients with delirium.
In this pre-post analysis, we decided a priori to compare patient outcomes during the baseline stage versus stage 3, after all QI interventions had been incrementally adopted into routine practice. All involved MICU staff received extensive training regarding this project. A daily checklist (available from authors) reminded staff to perform sleep-promoting interventions (16 (link)).
Kamdar B.B., King L.M., Collop N.A., Sakamuri S., Colantuoni E., Neufeld K.J., Bienvenu O.J., Rowden A.M., Touradji P., Brower R.G, & Needham D.M. (2013). The effect of a quality improvement intervention on perceived sleep quality and cognition in a medical ICU. Critical care medicine, 41(3), 800-809.
Publication 2012
Acquired Immunodeficiency Syndrome Antipsychotic Agents Benzodiazepines Blindness Caffeine Circadian Rhythms Critical Care Delirium Diphenhydramine Earplugs Haloperidol Light Milieu Therapy Opiate Alkaloids Patients Pharmaceutical Preparations Registered Nurse Sleep Sleep Stages Trazodone Zolpidem
5
Analyzing Adulteration in Illicit Drugs
Cited 3 times
Diphenhydramine tablets and capsules were purchased from a local grocery store (Top Care Brand, 25 mg). Analytical grade fentanyl standard was purchased from Sigma Aldrich (Cerilliant 1 mg/mL in 1 mL Methanol, Lot FE12281801). Alprazolam tablets, Gabapentin capsules, and Naloxone Buprenorphine tablets were obtained from the Marion County Deputy Coroner’s Office as artifacts from accidental overdose deaths. Sample identities were confirmed using pharmaceutical pill databases and liquid chromatography–mass spectrometry (LC–MS). Cocaine HCl, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA) were obtained from the Berrien County Forensic Laboratory as independent drug seizures. Street sample identity and purity was confirmed using Fourier-transform infrared spectroscopy (FTIR) and gas chromatography–mass spectrometry (GC–MS). These substances were selected based on reports from drug checkers at the Chicago Recovery Alliance and the perceived false positives on FTS during their analysis.
Lockwood T.L., Vervoordt A, & Lieberman M. (2021). High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips. Harm Reduction Journal, 18, 30.
Full text: Click here
Publication 2021
Accidents Alprazolam Buprenorphine Capsule Contraceptives, Oral Coroners Diphenhydramine Drug Overdose Fentanyl Gabapentin Gas Chromatography-Mass Spectrometry Hydrochloride, Cocaine Liquid Chromatography Mass Spectrometry MDMA Methamphetamine Methanol Naloxone Pharmaceutical Preparations Seizures Spectroscopy, Fourier Transform Infrared

Most recents protocols related to «Diphenhydramine»

1
Topical Treatment for Skin Condition
Not available on PMC !

Example 6

10 mg of diethylaminoethyl 2[(2,6-dichlorophenyl)amino]benzene acetate hydrochloride), 3 mg of diethylaminoethyl [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate, 0.5 mg of (RS)-6-[2-(tert-butylamino)-1-acetyloxyethyl]-2-(acetyloxymethyl)-3-acetyloxypyridine hydrochloride (or pirbuterol triacetate hydrochloride, a HPP of pirbuterol), and 10 mg of diphenhydramine [2-(diphenylmethoxy)-N,N-dimethylethanamine] in 0.5 ml of water was applied to the skin on the thorax of a subject every morning and evening (twice per day) until the condition was alleviated. Then 30 mg of diethylaminoethyl acetylsalicylate hydrochloride and 3 mg of diethylaminoethyl [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate hydrochloride in 0.5 ml of water was applied to the skin on the thorax of a subject every morning and evening (twice per day) to prevent the recurrence of the condition.

US11857545B2. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions (2024-01-02). TECHFIELDS PHARMA CO., LTD. [CN]. Inventors: Chongxi Yu [US], Lina Xu [CN].
Full text: Click here
Patent 2024
Acetate Allergic Conjunctivitis Benzene Chest Diphenhydramine Edan pirbuterol Pruritus Recurrence Rhinitis, Allergic Rhinorrhea Skin TERT protein, human
2
Retrospective Study of DPd Therapy in RRMM Patients
This retrospective study was conducted at the University of Kansas Medical Center (Westwood, KS, USA) in collaboration with the United States Myeloma Innovations Research Collaborative (USMIRC). The study covered the period between January 2015 and June 2022 and received approval from the University of Kansas Institutional Review Board and conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Subjects with a diagnosis of RRMM who received DPd in the second or subsequent lines of therapy were included. We reviewed electronic health records to extract relevant patient data including age, gender, race, MM type and stage, cytogenetics, and treatment lines including auto-HSCT. In addition, we obtained the hematological laboratory parameters of patients over the course of their DPd treatments, as well as any treatment-related adverse events described in their medical records.
The standard-of-care DPd regimen specified daratumumab administered weekly 16 mg/kg intravenously or 1,800 mg subcutaneously with hyaluronidase for the first 8 weeks, every 2 weeks from weeks 9 to 24, and then monthly until discontinuation of treatment due to disease progression or unacceptable toxicity. Pomalidomide dosage was 4 mg orally every day for 21 days as part of a 28-day cycle. Dexamethasone dosage was 20 mg weekly for patients aged 75 and older and 40 mg weekly for patients younger than 75. Antithrombotic and antiviral prophylaxis was carried out as recommended in clinical trials and practice guidelines. Patients were premedicated with glucocorticoids, acetaminophen, and diphenhydramine to prevent infusion reactions and, if required, with albuterol and montelukast in cases of underlying lung disease. Renal, hepatic, and hematological parameters were monitored during DPd therapy. Pomalidomide dosage was adjusted in line with the package insert if cytopenia occurred. Dose reduction was from 4 mg to 3 mg, then to 2 mg, and then to 1 mg; if the patient could not tolerate the lowest dose, pomalidomide was permanently discontinued. For daratumumab, there is no dose reduction, but delay in treatment until resolution of cytopenia and or infection.
Response to therapy was assessed using the International Myeloma Working Group (IMWG) criteria [12 (link)]. Grading of hematological and non-hematological adverse events was determined following the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [13 ]. Survival outcomes such as PFS and overall survival (OS) were estimated by means of Kaplan-Meier curves using log-rank testing.
Alkharabsheh O., Bellman P., Mahmoudjafari Z., Cui W., Atrash S., Paul B., Hashmi H., Shune L., Ahmed N, & Abdallah A.O. (2023). Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone. Journal of Hematology, 12(1), 1-6.
Publication 2023
Acetaminophen Albuterol Antiviral Agents daratumumab Dexamethasone Diagnosis Diphenhydramine Disease Progression Drug Tapering Ethics Committees, Research Gender Glucocorticoids Hyaluronidase Infection Innovativeness Kidney Lung Diseases montelukast Multiple Myeloma Patients pomalidomide Therapeutics Treatment Protocols Youth
3
Apatinib and Sintilimab with Chemotherapy
Apatinib was given as a fixed dose of 250 mg once a day, within 30 min after breakfast. Sintilimab was given within 60 min before chemotherapy by intravenous infusion of a fixed dose of 200 mg every 3 weeks. Antiemetic drugs were given by intravenous infusion 30 min before chemotherapy with either irinotecan (150 mg/m2, 90-minute intravenous infusion once every 2 weeks) or paclitaxel (150 mg/m2, 3-hour intravenous infusion once every 3 weeks). Considering that compared with monotherapy combination may increase the risk of toxic reactions, and chemotherapy is more important to play an immunomodulatory role in the combination therapy, the dose of chemotherapy drugs in this study was lowered compared with the conventional dose. Prophylactic atropine was given before the next irinotecan infusion treatment for patients with acute cholinergic syndrome. To prevent allergic reaction, 10 mg of oral dexamethasone was given 12 and 6 h before paclitaxel administration, and 400 mg of intravenous cimetidine and 50 mg of intramuscular diphenhydramine were given 30 min before paclitaxel administration. An intravenous infusion of sintilimab every 3 weeks is considered one cycle. Apatinib and sintilimab were continued until the disease progressed or became intolerable or up to 2 years, and the chemotherapy drug irinotecan or paclitaxel was continued until the disease progression, intolerable toxicity, or up to 6 months. If adverse events occurred during treatment, symptomatic and supportive treatments were given according to clinical protocol. Immune-related adverse events were treated with reference to the NCCN immune-related toxicity management guidelines. Blood or urine laboratory tests such as routine blood parameters, blood biochemistry, heart function, routine urinalysis, and thyroid function were regularly performed according to clinical protocol. Contrast-enhanced computed tomography of chest, abdomen, and pelvis was carried out every 6 weeks until progressive disease (PD) was confirmed. Response was determined by the investigators according to RECIST 1.1. Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Patients with PD after the study treatment were followed up every 3 months by telephone until death.
Zhang L., Wang W., Ge S., Li H., Bai M., Duan J., Yang Y., Ning T., Liu R., Wang X., Ji Z., Wang F., Zhang H., Ba Y, & Deng T. (2023). Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial. BMC Cancer, 23, 211.
Full text: Click here
Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Abdomen Allergic Reaction Antiemetics apatinib Atropine BLOOD Chest Cholinergic Agents Cimetidine Clinical Protocols Combined Modality Therapy Condoms Dexamethasone Diphenhydramine Disease Progression Heart Hematologic Tests Immunomodulation Intravenous Infusion Irinotecan Paclitaxel Patients Pelvis Pharmaceutical Preparations Pharmacotherapy sintilimab Syndrome Thyroid Gland Urinalysis Urine X-Ray Computed Tomography
4
Noscough® Syrup for Cough Symptoms
The patients in the Noscough® group received Noscough® syrup (Faran Shimi, Iran, each 5 mL contain 7 mg noscapine and 5 mg licorice extract), 20 mL every 6 h for 5 days. The control group received diphenhydramine (Pursina, Iran, each 5 mL contain 12.5 mg diphenhydramine) 7 mL every 8 h. No other medications were received. Patients in both groups received cetirizine 10 mg once daily for the relief of coryzal symptoms. Patients were allowed to leave the study at any time. Their demographic characteristics, underlying diseases, and medication histories were recorded at baseline.
Barati S., Feizabadi F., Khalaj H., Sheikhzadeh H., Jamaati H.R., Farajidavar H, & Dastan F. (2023). Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial. Frontiers in Pharmacology, 14, 1102940.
Full text: Click here
Publication 2023
Cetirizine Common Cold Diphenhydramine Glycyrrhiza Noscapine Patients Pharmaceutical Preparations
5
COVID-19 Cough Treatment Protocol
Patients over 18 years of age with cough and positive reverse transcriptase polymerase chain reaction (RT-PCR) test for COVID-19 with the onset time of less than 5 days were included in the study.
Exclusion criteria were as follows: pregnancy or breastfeeding, history of allergy to noscapine, licorice, diphenhydramine, morphine or other excipients of the study medications, history of seizure, diarrhea or diabetes, consumption of warfarin, benzodiazepines, opioid agonists, and other antitussive medications.
Barati S., Feizabadi F., Khalaj H., Sheikhzadeh H., Jamaati H.R., Farajidavar H, & Dastan F. (2023). Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial. Frontiers in Pharmacology, 14, 1102940.
Full text: Click here
Publication 2023
agonists Allergic Reaction Antitussive Agents Benzodiazepines Cough COVID 19 Diabetes Mellitus Diarrhea Diphenhydramine Excipients Glycyrrhiza glabra Morphine Noscapine Opioids Patients Pregnancy Reverse Transcriptase Polymerase Chain Reaction Seizures Warfarin

Top products related to «Diphenhydramine»

1
Diphenhydramine by Merck Group
Sourced in United States
Diphenhydramine is a chemical compound commonly used as a general-purpose laboratory reagent. It is a white crystalline solid with a melting point of approximately 168-172°C. Diphenhydramine is soluble in water and organic solvents, making it a versatile tool for various laboratory applications.
2
Methanol by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Germany, Belgium, Canada, France, India, Australia, Portugal, Spain, New Zealand, Ireland, Sweden, Italy, Denmark, Poland, Malaysia, Switzerland, Macao, Sao Tome and Principe, Bulgaria
Methanol is a colorless, volatile, and flammable liquid chemical compound. It is commonly used as a solvent, fuel, and feedstock in various industrial processes.
3
Verapamil by Merck Group
Sourced in United States, Germany, France, United Kingdom, China, Japan, Spain, Italy, Sao Tome and Principe, Switzerland, Australia, Ireland, Belgium
Verapamil is a laboratory product manufactured by Merck Group. It is a calcium channel blocker that inhibits the movement of calcium ions through cell membranes, which can affect various physiological processes. The core function of Verapamil is to serve as a research tool for the study of calcium-dependent mechanisms in biological systems.
4
Phosphate buffered saline (pbs) by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, Poland, Spain, France, Sao Tome and Principe, Australia, China, Canada, Ireland, Japan, Macao, Switzerland, India, Belgium, Denmark, Israel, Brazil, Austria, Portugal, Sweden, Singapore, Czechia, Malaysia, Hungary
PBS (Phosphate-Buffered Saline) is a widely used buffer solution in biological and medical research. It is a balanced salt solution that maintains a stable pH and osmotic pressure, making it suitable for a variety of applications. PBS is primarily used for washing, diluting, and suspending cells and biological samples.
5
Acetonitrile by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Belgium, Germany, Canada, Portugal, France, Australia, Spain, Switzerland, India, Ireland, New Zealand, Sweden, Italy, Japan, Mexico, Denmark
Acetonitrile is a highly polar, aprotic organic solvent commonly used in analytical and synthetic chemistry applications. It has a low boiling point and is miscible with water and many organic solvents. Acetonitrile is a versatile solvent that can be utilized in various laboratory procedures, such as HPLC, GC, and extraction processes.
6
Mycophenolate by Genentech
Mycophenolate is a lab equipment product used for immunosuppression. It is a chemical compound that inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for the de novo synthesis of guanine nucleotides. This mechanism of action leads to the inhibition of lymphocyte proliferation.
7
Methylprednisolone by Pfizer
Sourced in United States, Belgium, Italy, China
Methylprednisolone is a synthetic corticosteroid medication used as an anti-inflammatory and immunosuppressant drug. It is primarily used in the treatment of various inflammatory and autoimmune conditions.
8
Indomethacin by Merck Group
Sourced in United States, Germany, United Kingdom, Brazil, Italy, Sao Tome and Principe, China, India, Japan, Denmark, Australia, Macao, Spain, France, New Zealand, Poland, Singapore, Switzerland, Belgium, Canada, Argentina, Czechia, Hungary
Indomethacin is a laboratory reagent used in various research applications. It is a non-steroidal anti-inflammatory drug (NSAID) that inhibits the production of prostaglandins, which are involved in inflammation and pain. Indomethacin can be used to study the role of prostaglandins in biological processes.
9
Tetraethyl ammonium tea by Merck Group
Sourced in United States, United Kingdom, Germany
Tetraethyl ammonium (TEA) is a quaternary ammonium compound used as a laboratory reagent. It functions as a supporting electrolyte in electrochemical measurements and as a phase-transfer catalyst in organic synthesis.
10
Thymoglobulin by Sanofi
Sourced in United States, France, Canada, Germany, Ireland, Switzerland
Thymoglobulin is a polyclonal antithymocyte globulin (ATG) product developed by Sanofi. It is a sterile, purified, and concentrated immunoglobulin preparation derived from the plasma of horses immunized with human thymocytes. Thymoglobulin is used as an immunosuppressant to prevent and treat acute rejection in organ transplantation.

More about "Diphenhydramine"

Diphenhydramine is a widely used antihistamine medication that effectively alleviates symptoms associated with allergies, such as sneezing, itching, and hives.
This drug works by blocking the action of histamine, a chemical released by the body during an allergic reaction.
Diphenhydramine is available in various forms, including oral tablets, capsules, and liquids, making it a versatile treatment option for conditions like hay fever, insect bites, and certain skin rashes.
Researchers often utilize Diphenhydramine in their studies to better understand its pharmacological properties and explore potential therapeutic applications.
PubCompare.ai, an innovative platform, can assist scientists in optimizing their Diphenhydramine research by helping them identify the best protocols and approaches from the literature, preprints, and patents.
This can enhance the reproducibility and accuracy of their findings, leading to more reliable and effective methodologies.
Diphenhydramine is commonly compared to other medications like Methanol, Verapamil, and Mycophenolate in research studies.
These comparisons can provide valuable insights into the drug's mechanism of action, pharmacokinetics, and potential interactions.
Additionally, techniques like PBS (Phosphate-Buffered Saline), Acetonitrile, and Tetraethyl ammonium (TEA) are often utilized in Diphenhydramine research to facilitate various experimental procedures.
By leveraging the intelligent comparisons and comprehensive data available on PubCompare.ai, researchers can streamline their Diphenhydramine studies, ultimately improving the quality and impact of their work.
With its user-friendly interface and AI-driven capabilities, PubCompare.ai empowers scientists to navigate the vast expanse of literature, preprints, and patents, ensuring they have the most reliable and effective methodologies at their fingertips.